Home/Pipeline/Undisclosed TRAAC Program

Undisclosed TRAAC Program

Not Disclosed

Clinical (Phase not specified)Active

Key Facts

Indication

Not Disclosed

Phase

Clinical (Phase not specified)

Status

Active

Company

Tallac Therapeutics

About Tallac Therapeutics

Tallac Therapeutics is an innovative, clinical-stage biotech pioneering a novel class of immunostimulatory antibody-drug conjugates (ADCs). The company's TRAAC platform conjugates oligonucleotide payloads, like TLR9 agonists, to antibodies, aiming to precisely deliver immune-activating signals to the tumor while minimizing systemic toxicity. With two programs in the clinic, including lead candidate TAC-001 which has received FDA Fast Track designation, Tallac is advancing a pipeline designed to harness both innate and adaptive immunity against cancer. The company is privately held, founded in 2019, and based in San Mateo, California.

View full company profile

Therapeutic Areas

Oncology

Other Not Disclosed Drugs

Drug	Company	Phase	Status
SAGE-689	Sage Therapeutics	Phase 1	Paused
SAGE-904	Sage Therapeutics	Preclinical	Research
BO-212	Highlight Therapeutics	Research	Active
Newzen-138	Newzen Pharma	Not Disclosed	Active
Immunozen	Newzen Pharma	Not Disclosed	Active
Newzen-40	Newzen Pharma	Not Disclosed	Active
AbbVie Partnership Program(s)	EvolveImmune Therapeutics	Pre-clinical	Active
FYB209	Formycon	Preclinical/Technical Development	Active
FYB210	Formycon	Preclinical/Technical Development	Active
Undisclosed Target	Libra Therapeutics	Discovery	Active
Eli Lilly Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active
AstraZeneca Collaboration Program(s)	PepLib Biotech	Discovery/Pre-clinical	Active